These results hold promise for the development of novel therapeutic strategies that utilize PdL1,2LNPs and their encapsulated Pd(II) complexes to specifically target and enhance the expression of P53, potentially leading to more effective cancer treatments in the future. The gene discussed is TP53; the disease is cancer.